How Chronic Stress Disrupts Fat Tissue Through DPP-4 and GLP-1 Peptide Signaling
Chronic stress increases DPP-4 enzyme activity, which degrades GLP-1 and disrupts the adiponectin-cathepsin K axis needed for healthy fat cell development — effects reversed by DPP-4 knockout or GLP-1 receptor activation.
Quick Facts
What This Study Found
Chronic stress increased DPP-4, decreased GLP-1 levels, and disrupted adipocyte differentiation through the GLP-1/adiponectin-cathepsin K axis. DPP-4 deletion, exenatide treatment, and CTSK deletion all reversed stress-related fat tissue dysfunction.
Key Numbers
Used three mouse genotypes (DPP4+/+, DPP4-/-, CTSK-/-) to dissect the pathway under stress and non-stress conditions.
How They Did This
In vivo study using DPP4+/+, DPP4-/-, and CTSK-/- mice under 2 weeks of chronic psychosocial stress, with exenatide (GLP-1 agonist) intervention. In vitro studies using 3T3-L1 preadipocytes with CTSK silencing/overexpression. Measured plasma DPP4/GLP-1/CTSK/adiponectin, adipose tissue morphology, gene/protein expression, and macrophage infiltration.
Why This Research Matters
Chronic stress is a growing public health crisis linked to obesity and metabolic disease. This study reveals a specific molecular pathway — DPP-4/GLP-1/adiponectin — connecting psychological stress to fat tissue dysfunction, suggesting that GLP-1 drugs or DPP-4 inhibitors could protect metabolic health during periods of chronic stress.
The Bigger Picture
This study adds a metabolic dimension to the stress-disease connection. DPP-4 inhibitors (like sitagliptin) and GLP-1 drugs (like semaglutide) are already prescribed to millions. If chronic stress amplifies DPP-4 activity and GLP-1 degradation, these existing drugs may provide metabolic protection beyond their primary diabetes indications for stressed populations.
What This Study Doesn't Tell Us
Mouse chronic stress model may not fully replicate human psychological stress. Two-week duration is relatively short for chronic stress effects. The complex multi-knockout design makes pathway isolation challenging. Fat tissue biology differs between mice and humans.
Questions This Raises
- ?Do people with chronic stress show elevated DPP-4 levels and impaired GLP-1 signaling?
- ?Could DPP-4 inhibitors or GLP-1 drugs prevent stress-related metabolic dysfunction in clinical studies?
- ?Is the stress-DPP-4-GLP-1 pathway relevant to stress-induced obesity in humans?
Trust & Context
- Key Stat:
- Stress → DPP-4 → GLP-1 loss Chronic stress increases DPP-4 enzyme activity, degrading GLP-1 peptide and disrupting healthy fat tissue development
- Evidence Grade:
- Moderate evidence: comprehensive mouse study using multiple knockout models and both in vivo/in vitro approaches, published in FASEB Journal. No human data.
- Study Age:
- Published in 2024 in the FASEB Journal. Novel finding connecting psychological stress to GLP-1/DPP-4 axis disruption in fat tissue.
- Original Title:
- Dipeptidyl peptidase-4 disturbs adipocyte differentiation via the negative regulation of the glucagon-like peptide-1/adiponectin-cathepsin K axis in mice under chronic stress conditions.
- Published In:
- FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 38(10), e23684 (2024)
- Authors:
- Zhang, Meiping, Yue, Xueling, Xu, Shengnan(2), Piao, Jinshun, Zhao, Longguo, Shu, Shangzhi, Kuzuya, Masafumi, Li, Ping, Hong, Lan, Kim, Weon, Liu, Bin, Cheng, Xian Wu
- Database ID:
- RPEP-09645
Evidence Hierarchy
Frequently Asked Questions
Can chronic stress affect my metabolism?
Yes. This study shows chronic stress increases DPP-4 enzyme activity in mice, which breaks down the metabolic peptide GLP-1. This disrupts fat tissue development and contributes to metabolic dysfunction. The same pathway may operate in chronically stressed humans.
Could diabetes drugs protect against stress-related metabolic damage?
This mouse study found that both DPP-4 deletion and GLP-1 receptor activation reversed stress-related fat tissue dysfunction. This suggests DPP-4 inhibitors (like sitagliptin) and GLP-1 drugs (like semaglutide) could theoretically provide metabolic protection during stress, but human studies are needed.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09645APA
Zhang, Meiping; Yue, Xueling; Xu, Shengnan; Piao, Jinshun; Zhao, Longguo; Shu, Shangzhi; Kuzuya, Masafumi; Li, Ping; Hong, Lan; Kim, Weon; Liu, Bin; Cheng, Xian Wu. (2024). Dipeptidyl peptidase-4 disturbs adipocyte differentiation via the negative regulation of the glucagon-like peptide-1/adiponectin-cathepsin K axis in mice under chronic stress conditions.. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 38(10), e23684. https://doi.org/10.1096/fj.202400158R
MLA
Zhang, Meiping, et al. "Dipeptidyl peptidase-4 disturbs adipocyte differentiation via the negative regulation of the glucagon-like peptide-1/adiponectin-cathepsin K axis in mice under chronic stress conditions.." FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2024. https://doi.org/10.1096/fj.202400158R
RethinkPeptides
RethinkPeptides Research Database. "Dipeptidyl peptidase-4 disturbs adipocyte differentiation vi..." RPEP-09645. Retrieved from https://rethinkpeptides.com/research/zhang-2024-dipeptidyl-peptidase4-disturbs-adipocyte
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.